$147 Million

COMPASS Pathways

Initial Public Offering

Lead Left Bookrunner, September 2020

COMPASS Pathways

COMPASS Pathways plc is a biopharma company pioneering the development of psilocybin therapy, with an initial focus on treatment-resistant depression (TRD), a subset of major depressive disorder (MDD), comprising 100 million patients who are not helped after two or more antidepressant treatments. The Company has developed a proprietary, synthesized crystalline formulation of psilocybin, COMP360. The Company’s psilocybin therapy comprises administration of COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications.